Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
59.65
+0.64 (1.08%)
Sep 3, 2026, 4:00 PM EDT - Market closed
Enliven Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Enliven Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $73.9. The average 1-year stock price forecast is 23.89% higher than the current stock price, while the lowest is $64 (+7.29%) and the highest is $82 (+37.47%).
Price Target: $73.9 (+23.89%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Enliven Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 10 | 10 | 11 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 10 | 10 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 22, 2026 |
| Barclays | Barclays | Buy Initiates $78 | Buy | Initiates | $78 | +30.76% | Aug 18, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $62 → $73 | Buy | Maintains | $62 → $73 | +22.38% | Aug 17, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $82 | Buy | Reiterates | $82 | +37.47% | Aug 13, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $60 → $70 | Buy | Reiterates | $60 → $70 | +17.35% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
6.25K
EPS This Year
-1.85
from -1.83
EPS Next Year
-2.34
from -1.85
EPS and Forward PE are based on non-GAAP adjusted numbers.